CA3025234A1 - Cmv epitopes - Google Patents

Cmv epitopes Download PDF

Info

Publication number
CA3025234A1
CA3025234A1 CA3025234A CA3025234A CA3025234A1 CA 3025234 A1 CA3025234 A1 CA 3025234A1 CA 3025234 A CA3025234 A CA 3025234A CA 3025234 A CA3025234 A CA 3025234A CA 3025234 A1 CA3025234 A1 CA 3025234A1
Authority
CA
Canada
Prior art keywords
subject
cmv
cell
peptide
apc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3025234A
Other languages
English (en)
French (fr)
Inventor
Rajiv Khanna
Corey Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QIMR Berghofer Medical Research Institute
Original Assignee
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queensland Institute of Medical Research QIMR filed Critical Queensland Institute of Medical Research QIMR
Publication of CA3025234A1 publication Critical patent/CA3025234A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3025234A 2016-05-23 2017-05-23 Cmv epitopes Pending CA3025234A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340223P 2016-05-23 2016-05-23
US62/340,223 2016-05-23
PCT/IB2017/000849 WO2017203370A2 (en) 2016-05-23 2017-05-23 Cmv epitopes

Publications (1)

Publication Number Publication Date
CA3025234A1 true CA3025234A1 (en) 2017-11-30

Family

ID=60412168

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3025234A Pending CA3025234A1 (en) 2016-05-23 2017-05-23 Cmv epitopes

Country Status (7)

Country Link
US (2) US20200316119A1 (enExample)
EP (1) EP3463400A4 (enExample)
JP (2) JP2019520332A (enExample)
CN (1) CN109475579A (enExample)
AU (3) AU2017271136A1 (enExample)
CA (1) CA3025234A1 (enExample)
WO (1) WO2017203370A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
CA3100420A1 (en) * 2018-05-18 2019-11-21 The Council Of The Queensland Institute Of Medical Research Adoptive t-cell therapy for cmv infection and cmv-associated diseases
MX2021002702A (es) 2018-09-10 2021-05-12 Atara Biotherapeutics Inc Metodos para expandir celulas t del receptor de antigeno quimerico especificas de antigenos, composiciones y usos relacionados con las mismas.
US20260055195A1 (en) * 2019-10-09 2026-02-26 The Council Of The Queensland Institute Of Medical Research Targeting epha3 and uses thereof
BR112022021769A2 (pt) * 2020-04-28 2022-12-13 Council Queensland Inst Medical Res Composição de vacina de poliepítopo de citomegalovírus humano
CN111875698B (zh) * 2020-07-29 2021-11-05 广州呈源生物免疫技术有限公司 靶向hcmv的tcr及其获得方法和应用
KR102769935B1 (ko) * 2021-03-30 2025-02-19 한국과학기술원 펩타이드-mhc에 대한 t 세포 활성의 예측 방법 및 분석장치

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041442B1 (en) * 1999-06-04 2006-05-09 Florian Kern Peptides for vaccinating against human CMV
DE10009341A1 (de) * 2000-02-22 2001-09-06 Florian Kern Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
AUPR593101A0 (en) * 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
PT1651666E (pt) * 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
AU2012227280B2 (en) * 2004-11-29 2016-09-22 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
WO2006056027A1 (en) * 2004-11-29 2006-06-01 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
US20110136896A1 (en) * 2008-08-01 2011-06-09 Tong-Ming Fu Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
GB0917094D0 (en) * 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
EP2812431B1 (en) * 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
WO2013170305A1 (en) * 2012-05-16 2013-11-21 Adelaide Research & Innovation Pty Ltd Cellular vaccine and method of inducing an immune response in a subject
GB201312133D0 (en) * 2013-07-05 2013-08-21 Univ Birmingham Immunotherapy
US9757446B2 (en) * 2014-03-17 2017-09-12 Flugen, Inc. Influenza virus vectors and uses therefor

Also Published As

Publication number Publication date
AU2023201279A1 (en) 2023-04-20
EP3463400A2 (en) 2019-04-10
AU2026203085A1 (en) 2026-05-21
WO2017203370A2 (en) 2017-11-30
CN109475579A (zh) 2019-03-15
WO2017203370A3 (en) 2018-02-01
US20200316119A1 (en) 2020-10-08
EP3463400A4 (en) 2020-07-29
JP2019520332A (ja) 2019-07-18
AU2017271136A1 (en) 2019-01-03
US20250127874A1 (en) 2025-04-24
JP2023071724A (ja) 2023-05-23

Similar Documents

Publication Publication Date Title
US20250127874A1 (en) Cmv epitopes
US12291559B2 (en) Compositions and methods for treating cancer
AU2024204269A1 (en) HPV Immunotherapy
AU2024219637A1 (en) Adoptive t-cell therapy for cmv infection and cmv-associated diseases
AU2018210375A1 (en) Methods of treating multiple sclerosis using autologous t cells
US20230381298A1 (en) Herpesvirus polyepitope vaccines
WO2025241005A1 (en) Enhanced chimeric antigen receptor t cell composition and method of use
EP4687959A1 (en) Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer
HK40040260A (en) Hpv immunotherapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220524

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241119

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250319

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250331

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250514

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250514

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250715

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250715

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260113

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260511

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260511

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260513

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260630